Skip Ribbon Commands
Skip to main content
Menu
Assoc Prof Lee Lui Shiong

Assoc Prof Lee Lui Shiong

MBBS (S’pore), MRCS (Edin), M Med (Surg)

Head & Senior Consultant

Sengkang General Hospital

Specialty: Surgery & Surgical Oncology

Sub-specialties: Uro-Oncology

Conditions Treated by this Doctor:
Tumours of the prostate, kidney, bladder, testes and adrenal gland.

Clinical Appointments

  • Head & Senior Consultant Department of Urology Sengkang General HospitalSengkang General Hospital
  • Visiting Consultant National Cancer Centre SingaporeNational Cancer Centre Singapore

Profile

Dr Lee Lui Shiong completed undergraduate education at the National University of Singapore in 2002 and obtained postgraduate qualifications of MRCS (Edinburgh) and MMed (Surgery) in 2005. In 2010, he was awarded the College of Surgeons Gold Medal in Urology, as the most outstanding urology trainee. 

He is a Senior Consultant and Head in the Department of Urology, Sengkang General Hospital. He is a visiting consultant National Cancer Centre. He is also Vice President Singapore Urological Association and SKH Site Director, SingHealth Urology Residency.

He has a keen clinical interest in urological cancer treatment and research. 

Education

  • MBBS (S’pore)
  • MRCS (Edin)
  • M Med (Surg)

Professional Appointments and Committee Memberships

  • Senior Clinical Lecturer, ​Yong Loo Lin School of Medicine, National University of Singapore
  • Adjunct Associate Professor, Duke-NUS Medical School
  • Member of the Royal College of Surgeons (Edinburgh)
  • Fellow, Academy of Medicine Singapore
  • Singapore Urological Association (SUA)

Awards

  • SingHealth Service Quality Gold Award, 2022
  • SingHealth Service Quality Silver Award, 2020
  • Health Service Awards, Gold Award, SGH, 2016
  • Service from the Heart Award, SGH, 2014 & 2009
  • Fellowship, NMRC Research Training, NMRC, 2011
  • Fellowship, HMDP Award, Ministry of Health, 2010
  • College of Surgeons Gold Medal Award (Urology), 2010

Research Interests

Publications

  1. Lee LS, et al. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2022 Jan 28. doi: 10.1038/s41391-022-00496-8
  2. Teoh, J.YC., Chan, Lee LS., et al. Perioperative Outcomes of Robot-Assisted Radical Cystectomy with Intracorporeal Versus Extracorporeal Urinary Diversion. Ann Surg Oncol 28, 9209–9215 (2021). https://doi.org/10.1245/s10434-021-10295-5
  3. Tan YG, … Lee, L.S. Benefits of robotic cystectomy compared with open cystectomy in an Enhanced Recovery After Surgery program: A propensity‐matched analysis. Int Journal of Urology 2020; July 2020. 
  4. Daanesh Huned, Raj Tiwari, Kae Jack Tay, Lui Shiong Lee. The Benefit of Robotic Surgery in Postradiorecurrent Invasive Bladder Cancer. 2020 Videoscopy (Doi:https://doi.org/10.1089/vor.2021.0002)
  5. Shui Hui Neo, .., Lui Shiong Lee.. Technical Considerations for Bipolar Enblock Resection of Bladder Tumors. Videourology 2021 (https://doi.org/10.1089/vid.2020.0113)
  6. Alvin Lee Yuanming, … Lui Shiong Lee. The Uro- Oncology Multi-disciplinary team (MDT) Clinic – Clinical and Patient-Reported Outcomes From Implementing a New Model of Care. Proceedings of Singapore Healthcare. Nov 2021

Research Trials

 

  1. May 2017 – April 2019, Neoadjuvant apalutamide (ARN509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer, SGD55,000.
  2. May 2017 – April 2018, Using cell free DNA for treatment prognostication in organ confined prostate cancer, SGD75,000.
  3. March 2016 – Feb 2018, Graphene Oxide-based Detection of Urinary microRNAs for the Diagnosis of Prostate Cancer  Amongst Senior Age Men, SGD153,000.
  4. Oct 2014 – Sep 2017, Research Project Title: Fluorescence guided diagnosis of prostate cancer with a PSMA small  molecule-indocyanine green (ICG) conjugate, SGD35,000.
  5. June 2016 – May 2017, Establishing a Genomic Correlation between Circulating Tumour Cells and Primary Tumour in  High Risk Non-metastatic Prostate Cancer: A Pilot Study, SGD30,000.
  6. Sep 2016 – Sep 2017, Dynamic Release of Local Anaesthetics through Novel Tissue Adhesives, SGD25,000.